Minimal residual disease surveillance at day 90 predicts long-term survival in pediatric patients with T-cell acute lymphoblastic leukemia

Liu, Xiaoming; Zou, Yao; Chen, Xiaojuan; Wang, Shuchun; Guo, Ye; Yang, Wenyu; Zhang, Li; Chen, Yumei; Zhang, Yingchi; Zhu, Xiaofan

doi:10.1080/10428194.2020.1805739

Cited by 4 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The introduction of FC-MRD further refined the risk classification of T-ALL, and the treatment efficacy also improved to a certain extent. This study showed that the efficacy of the 2015 regimen for T-ALL was significantly higher than the results of previous domestic trials ( 6 , 12 ), and slightly lower than the international advanced level (AALL0434 trial) ( 3 ). However, it was obvious that the CCCG-ALL-2015 program could not effectively distinguish children with T-ALL at different risk levels (0 cases at standard risk, 102 cases at intermediate risk, and 3 cases at high risk).…”

Section: Discussioncontrasting

confidence: 66%

“…After reviewing the CCLG-ALL-2008 program, we found that adjusting the risk group and the treatment of children with T-ALL according to the MRD level may improve the therapeutic efficacy. In previous conventional regimes, e.g., CCGL-ALL-2008, the time point of MRD monitoring at 90 days showed the most predictive value for the prognosis of children ( 12 ). However, in the CCCG-ALL-2015 plan, we focused on the principle of non-inferiority to reduce the intensity of chemotherapy as much as possible, introduced intensive treatment (CAM) on the 29th day of VDLP induction therapy, and reduced the two-CAM course (28 days in total) to one 7-day CAM.…”

Section: Discussionmentioning

confidence: 84%

“…ALL was diagnosed if at least 25% of lymphoblasts were present in the bone marrow (BM). T-cell lineage features of leukemic cells were determined according to standard techniques ( 11 , 12 ) ( Supplementary Table 1 ). Enrollment in the CCCG-ALL-2015 classification/biology study was required for study entry ( 13 , 14 ).…”

Section: Methodsmentioning

confidence: 99%

“…Enrollment in the CCCG-ALL-2015 classification/biology study was required for study entry ( 13 , 14 ). Minimal residual disease (MRD) testing was performed at our hospital by flow cytometry using established methodologies ( 12 ) on days 19 and 46 of treatment ( Supplementary Table 2 ). The sensitivity of MRD testing was 0.01%.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

A Novel Risk Defining System for Pediatric T-Cell Acute Lymphoblastic Leukemia From CCCG-ALL-2015 Group

et al. 2022

Self Cite

View full text Add to dashboard Cite

ObjectiveT-cell acute lymphoblastic leukemia (T-ALL) is a rare hematological malignancy with a poor prognosis. The present study aims to identify the precise risk grouping of children with T-ALL.MethodsWe analyzed the outcomes for 105 consecutive patients treated using the Chinese Children’s Cancer Group ALL-2015 (CCCG-ALL-2015) protocol registered with the Chinese Clinical Trial Registry (ChiCTR-IPR-14005706) between 2015 and 2020 in our center. Nine out of 21 clinical and biological indicators were selected for the new scoring system based on the analysis in this study.ResultsThe 5-year overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) rates for the 105 patients were 83.1 ± 4.8%, 72.4 ± 5.6%, and 78.4 ± 3.6%, respectively. Based on the new scoring system, 90 evaluable children were regrouped into low-risk (n=22), intermediate-risk (n=50), and high-risk (n=18) groups. The 5-year survival (OS, EFS, and RFS) rates for all patients in the low-risk group were 100%, significantly higher than the rates for those in the intermediate-risk group (91.2 ± 5.2%, 74.4 ± 8.6%, and 82.5 ± 6.2%, respectively) and high-risk group (59.0 ± 13.2%, 51.9 ± 12.4%, and 51.9 ± 12.4%, respectively) (all P values < 0.01).ConclusionThe CCCG-ALL-2015 program significantly improved the treatment outcomes for childhood T-ALL as compared with the CCCG-ALL-2008 protocol. Our new refined risk grouping system showed better stratification among pediatric T-ALL patients and better potential in evaluating therapeutic efficacy.

show abstract

Section: Discussioncontrasting

confidence: 66%

Section: Discussionmentioning

confidence: 84%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

A Novel Risk Defining System for Pediatric T-Cell Acute Lymphoblastic Leukemia From CCCG-ALL-2015 Group

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

Clinical Analysis of Pediatric T-Cell Acute Lymphoblastic Leukemia Using the MRD-Oriented Strategy System

Xue¹,

Wang²,

et al. 2023

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Why Do Children with Acute Lymphoblastic Leukemia Fare Better Than Adults?

Neaga

Jimbu

Mesaros

et al. 2021

Cancers

View full text Add to dashboard Cite

It is a new and exciting time for acute lymphoblastic leukemia (ALL). While nearly 50 years ago, only one in nine children with ALL survived with chemotherapy, nowadays nearly 90% of children have a chance of long-term survival. Adults with ALL, as well as the special category of adolescents and young adult (AYA) patients, are catching up with the new developments seen in children, but still their prognosis is much worse. A plethora of factors are regarded as responsible for the differences in treatment response, such as age, ethnicity, disease biology, treatment regimens and toxicities, drug tolerance and resistance, minimal residual disease evaluation, hematopoietic stem cell transplantation timing and socio-economic factors. Taking these factors into account, bringing pediatric-like protocols to adult patient management and incorporating new agents into frontline treatment could be the key to improve the survival rates in adults and AYA.

show abstract

Minimal residual disease surveillance at day 90 predicts long-term survival in pediatric patients with T-cell acute lymphoblastic leukemia

Cited by 4 publications

References 28 publications

A Novel Risk Defining System for Pediatric T-Cell Acute Lymphoblastic Leukemia From CCCG-ALL-2015 Group

A Novel Risk Defining System for Pediatric T-Cell Acute Lymphoblastic Leukemia From CCCG-ALL-2015 Group

Clinical Analysis of Pediatric T-Cell Acute Lymphoblastic Leukemia Using the MRD-Oriented Strategy System

Why Do Children with Acute Lymphoblastic Leukemia Fare Better Than Adults?

Contact Info

Product

Resources

About